Study of Paclitaxel for Liver Cancer
Author Information
Author(s): Y Chao, W-K Chan, MJ Birkhofer, OY-P Hu, S-S Wang, Y-S Huang, M Liu, J Whang-Peng, K-H Chi, W-Y Lui, S-D Lee
Primary Institution: Veterans General Hospital-Taipei and National Yang-Ming University
Hypothesis
Does paclitaxel have any significant anti-cancer effect in patients with unresectable hepatocellular carcinoma?
Conclusion
Paclitaxel has no significant anti-cancer effect in patients with unresectable hepatocellular carcinoma.
Supporting Evidence
- No complete or partial responses were observed in the study.
- The median survival of patients was 12 weeks.
- Treatment-related deaths occurred in two patients.
Takeaway
This study tested a cancer drug called paclitaxel on patients with a serious liver cancer, but it didn't help them get better.
Methodology
Patients received paclitaxel intravenously every 3 weeks, and their responses and side effects were monitored.
Limitations
The study had a small sample size and no complete or partial responses were observed.
Participant Demographics
Median age was 64 years, all patients had cirrhosis, and most had chronic hepatitis B or C.
Statistical Information
P-Value
p=0.03
Statistical Significance
p<0.02
Want to read the original?
Access the complete publication on the publisher's website